The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 229K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grimm, M.C.
Right arrow Articles by Oppenheim, J.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grimm, M.C.
Right arrow Articles by Oppenheim, J.J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/7/317/ $5.00
The Journal of Experimental Medicine, Volume 188, Number 2, July 20, 1998 317-325

Articles

Opiates Transdeactivate Chemokine Receptors: {delta} and µ Opiate Receptor–mediated Heterologous Desensitization

M.C. Grimm*, A. Ben-Baruch*, D.D. Taub||, O.M.Z. Howard{ddagger}, J.H. Resau§, J.M. Wang{ddagger}, H. Ali, R. Richardson, R. Snyderman, and J.J. Oppenheim*

From the * Laboratory of Molecular Immunoregulation, Division of Basic Sciences, and the {ddagger} Intramural Research Support Program, Science Applications International Corp. Frederick, Frederick, Maryland 21702; the § ABL–Basic Research Program, National Cancer Institute – Frederick Cancer Research and Development Center, Frederick, Maryland 21702; the || Laboratory of Immunology, National Institute on Aging, Baltimore, Maryland 21224; and the Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710

An intact chemotactic response is vital for leukocyte trafficking and host defense. Opiates are known to exert a number of immunomodulating effects in vitro and in vivo, and we sought to determine whether they were capable of inhibiting chemokine-induced directional migration of human leukocytes, and if so, to ascertain the mechanism involved. The endogenous opioid met-enkephalin induced monocyte chemotaxis in a pertussis toxin–sensitive manner. Met-enkephalin, as well as morphine, inhibited IL-8–induced chemotaxis of human neutrophils and macrophage inflammatory protein (MIP)-1{alpha}, regulated upon activation, normal T expressed and secreted (RANTES), and monocyte chemoattractant protein 1, but not MIP-1β–induced chemotaxis of human monocytes. This inhibition of chemotaxis was mediated by {delta} and µ but not {kappa} G protein–coupled opiate receptors. Calcium flux induced by chemokines was unaffected by met-enkephalin pretreatment. Unlike other opiate-induced changes in leukocyte function, the inhibition of chemotaxis was not mediated by nitric oxide. Opiates induced phosphorylation of the chemokine receptors CXCR1 and CXCR2, but neither induced internalization of chemokine receptors nor perturbed chemokine binding. Thus, inhibition of chemokine-induced chemotaxis by opiates is due to heterologous desensitization through phosphorylation of chemokine receptors. This may contribute to the defects in host defense seen with opiate abuse and has important implications for immunomodulation induced by several endogenous neuropeptides which act through G protein–coupled receptors.

Key Words: chemokine • chemokine receptor • opioid receptor • desensitization • neuropeptide

Address correspondence to Michael C. Grimm, Laboratory of Molecular Immunoregulation, National Cancer Institute – Frederick Cancer Research and Development Center, Bldg. 560, Rm. 31-19, Frederick, MD 21702-1201. Phone: 301-846-1347; Fax: 301-846-7042; E-mail: grimm{at}mail.ncifcrf.gov

This research is sponsored in part by the National Cancer Institute, Department of Health and Human Services, under contract with ABL. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

Abbreviations used: CCR, CC chemokine receptor; CXCR, CXC chemokine receptor; CTOP, cys2, tyr3, orn5, pen7 amide; DAMGO, [D-ala2,N-me-phe-gly5(ol)]-enkephalin; MCP, monocyte chemoattractant protein; MIP, macrophage-inflammatory protein; NAP, neutrophil-activating peptide; NO, nitric oxide; RANTES, regulated upon activation, normal T expressed and secreted; STM, seven transmembrane–spanning.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS